Abstract
Cytomegalovirus (CMV) is a major cause of serious morbidity following solid organ transplantation via both direct and indirect mechanisms. The aim of this study was to investigate the efficacy and safety of valacyclovir prophylaxis in heart transplant recipients. Twenty-seven CMV seropositive adults due to receive a heart transplant were included in a single-center, randomized, double-blind study. Patients were randomized to receive either oral valacyclovir 2000 mg or oral acyclovir 200 mg four times daily starting within 3 days of heart transplant and continuing for 90 days. The primary outcome measure was time to development of CMV antigenemia assessed for 6 months after surgery. Other measures were time to asymptomatic CMV infection, symptomatic CMV infections, and end-organ CMV disease. Patients were monitored for other herpes infections, other opportunistic infections, and acute graft rejection. Safety was assessed by evaluating changes in hematology and clinical chemistry parameters and by the occurrence of adverse events. The median time to CMV antigenemia was 19 days for the acyclovir group compared with 119 days for the valacyclovir group (hazard ratio 0.42; 95% CI, 0.18-0.99; p = 0.049). Similar delays of approximatel...Continue Reading
References
Apr 27, 1978·The New England Journal of Medicine·K H RandT C Merigan
Apr 30, 1992·The New England Journal of Medicine·T C MeriganR M Ratkovec
Sep 1, 1990·Reviews of Infectious Diseases·R H Rubin
May 1, 1988·The Pediatric Infectious Disease Journal·R B Pollard
May 25, 1989·The New England Journal of Medicine·H H BalfourD S Fryd
Jun 23, 1989·JAMA : the Journal of the American Medical Association·M T GrattanN E Shumway
Dec 1, 1985·The Journal of Infectious Diseases·J S DummerH T Bahnson
Jan 1, 1995·Thorax·J J EganJ Craske
Jun 1, 1993·Transplantation·J M McCarthyP A Keown
May 15, 1996·Transplantation·R PatelC V Paya
Dec 31, 1997·Lancet·E GaneC A Robinson
Apr 1, 1998·Transplantation·J J EganA A Woodcock
May 13, 1999·The New England Journal of Medicine·D LowanceI C Lee
Citations
Sep 25, 2003·Journal of Cutaneous Medicine and Surgery·Jashin J WuStephen K Tyring
Oct 22, 2004·Current Treatment Options in Cardiovascular Medicine·Michael A Mathier, Dennis M McNamara
Sep 28, 2002·The Journal of Infectious Diseases·Jean-Paul Squifflet, Christophe Legendre
Sep 28, 2002·The Journal of Infectious Diseases·Per Ljungman
Jun 28, 2003·Transplantation·Glen P WestallThomas C Kotsimbos
Dec 30, 2009·Antimicrobial Agents and Chemotherapy·James P SmithDavid W Haas
Jun 21, 2005·Lancet·Elisabeth M HodsonJonathan C Craig
Dec 21, 2002·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Julien BaudBruno Hurault de Ligny
Dec 2, 2004·Expert Opinion on Emerging Drugs·Arun ChakrabartyStephen K Tyring
Jun 16, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M E Falagas, K Z Vardakas
Oct 9, 2007·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Supha Kijpittayarit-ArthursRaymund R Razonable
Jun 12, 2010·Expert Opinion on Pharmacotherapy·Karen J Vigil, Roy F Chemaly
Jun 15, 2006·Expert Review of Anti-infective Therapy·Julie S BrantleyStephen K Tyring
Feb 22, 2008·Journal of Cardiovascular Pharmacology and Therapeutics·Nasir Z SulemanjeeErnst R Schwarz
Jan 5, 2005·Circulation·JoAnn LindenfeldGeraldine G Miller
Mar 2, 2013·The Cochrane Database of Systematic Reviews·Elisabeth M HodsonJonathan C Craig
Mar 2, 2013·The Cochrane Database of Systematic Reviews·Daniel S OwersElisabeth M Hodson
Dec 3, 2016·Expert Review of Anti-infective Therapy·C L Abad, R R Razonable
Aug 8, 2020·Annals of Clinical Microbiology and Antimicrobials·Yu ZhangQiang Xia